Aptose Biosciences (APTO) News Today → This Wall Street stock prediction just went viral (From Chaikin Analytics) (Ad) Free APTO Stock Alerts $1.21 -0.02 (-1.63%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 4:54 AM | americanbankingnews.comStockNews.com Lowers Aptose Biosciences (NASDAQ:APTO) to SellMay 14 at 4:01 PM | globenewswire.comAptose Reports Results for the First Quarter 2024May 12, 2024 | americanbankingnews.comAptose Biosciences (APTO) Scheduled to Post Quarterly Earnings on TuesdayMay 12, 2024 | americanbankingnews.comAptose Biosciences Inc. (NASDAQ:APTO) Receives Average Rating of "Buy" from BrokeragesMay 6, 2024 | globenewswire.comAptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024March 29, 2024 | investing.comAptose Biosciences target cut, maintains buy rating on new drug developmentMarch 28, 2024 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Reports Results for the Fourth Quarter and Full Year 2023March 27, 2024 | finance.yahoo.comAptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | msn.comEdgewood secures $20m in Series A for clinical development of cancer therapyMarch 27, 2024 | benzinga.comRecap: Aptose Biosciences Q4 EarningsMarch 26, 2024 | globenewswire.comAptose Reports Results for the Fourth Quarter and Full Year 2023March 18, 2024 | globenewswire.comAptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024January 29, 2024 | finance.yahoo.comThis Aptose Biosciences Insider Increased Their Holding In The Last YearJanuary 26, 2024 | marketwatch.comAptose Biosciences Shares Drop 11% After Private, Public OfferingsJanuary 26, 2024 | markets.businessinsider.comAptose Prices Offering Of About 4.91 Mln Shares At $1.71/Share, $4 Private Placement With HanmiJanuary 26, 2024 | finance.yahoo.comAptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi PharmaceuticalJanuary 26, 2024 | investorplace.comWhy Is Aptose Biosciences (APTO) Stock Down Today?December 21, 2023 | benzinga.comAptose Biosciences Stock (NASDAQ:APTO), Guidance and ForecastDecember 5, 2023 | morningstar.comAptose Biosciences Inc APTODecember 4, 2023 | msn.comAptose Biosciences files to sell ordinary shares, warrantsDecember 1, 2023 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive RoleNovember 12, 2023 | seekingalpha.comAptose Biosciences Inc. (APTO) Q3 2023 Earnings Call TranscriptNovember 11, 2023 | benzinga.comAptose Biosciences Stock (NASDAQ:APTO) Earnings Dates and Earning CallsNovember 10, 2023 | benzinga.comAptose Biosciences: Q3 Earnings InsightsNovember 10, 2023 | markets.businessinsider.comPromising Financial Performance and Clinical Developments Bolster Aptose Biosciences’ Buy Rating: An Analysis by Joseph PantginisNovember 9, 2023 | msn.comAptose Biosciences GAAP EPS of -$1.76 beats by $0.22November 1, 2023 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)November 1, 2023 | markets.businessinsider.comPromising Trial Data and Expansion Plans Boost Confidence in Aptose Biosciences: An Analysis of John Newman’s Buy RatingOctober 30, 2023 | finance.yahoo.comAptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug TuspetinibOctober 16, 2023 | finance.yahoo.comAptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International ConferenceOctober 12, 2023 | theglobeandmail.comAptose Biosciences: Bottom 25 Performing Stocks Year-to-Date on TSX (APS)September 8, 2023 | finance.yahoo.comCompanies Like Aptose Biosciences (TSE:APS) Could Be Quite RiskySeptember 7, 2023 | finance.yahoo.comHANMI FILES EARLY WARNING REPORT IN RESPECT OF APTOSE BIOSCIENCES INC.September 7, 2023 | markets.businessinsider.comExpert Ratings for Aptose BiosciencesAugust 29, 2023 | marketbeat.comShort Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Declines By 12.8%Aptose Biosciences Inc. (NASDAQ:APTO - Get Free Report) (TSE:APS) saw a large decline in short interest in August. As of August 15th, there was short interest totalling 40,700 shares, a decline of 12.8% from the July 31st total of 46,700 shares. Based on an average daily trading volume, of 47,600 shares, the days-to-cover ratio is presently 0.9 days. Approximately 1.3% of the shares of the stock are sold short.August 24, 2023 | finance.yahoo.comAptose to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 23, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc down on Tuesday (APS)August 18, 2023 | fool.comAptose Biosciences (NASDAQ: APTO)August 11, 2023 | markets.businessinsider.comRBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To KnowAugust 11, 2023 | marketbeat.comRoyal Bank of Canada Cuts Aptose Biosciences (NASDAQ:APTO) Price Target to $23.00Royal Bank of Canada decreased their price target on shares of Aptose Biosciences from $40.00 to $23.00 in a report on Friday.August 11, 2023 | marketbeat.comAptose Biosciences Inc. (NASDAQ:APTO) Receives Consensus Rating of "Buy" from AnalystsShares of Aptose Biosciences Inc. (NASDAQ:APTO - Get Free Report) (TSE:APS) have earned an average recommendation of "Buy" from the five analysts that are covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 12 month price targAugust 11, 2023 | msn.comAptose Biosciences GAAP EPS of -$2.27 misses by $0.34August 2, 2023 | msn.comAptose Biosciences (APTO) Price Target Increased by 1614.75% to 62.90July 28, 2023 | finance.yahoo.comAptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023June 27, 2023 | finance.yahoo.comAPTO - Aptose Biosciences Inc.June 26, 2023 | finance.yahoo.comAptose Biosciences Meets Nasdaq Minimum Bid Price ComplianceJune 12, 2023 | marketwatch.comAptose Shares Up 11% After Study Presentation, Analysts' Target BoostsJune 12, 2023 | benzinga.comOppenheimer Maintains Outperform on Aptose Biosciences, Raises Price Target to $50June 12, 2023 | benzinga.comAptose Biosciences shares are trading higher after multiple firms raised their respective price targets.June 10, 2023 | markets.businessinsider.comJonesTrading Keeps Their Buy Rating on Aptose Biosciences (APTO) Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Look Who Fired the World’s Richest Man (Ad)This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S. And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman. Get the full story here. APTO Media Mentions By Week APTO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APTO News Sentiment▼0.670.55▲Average Medical News Sentiment APTO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APTO Articles This Week▼81▲APTO Articles Average Week Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Evaxion Biotech A/S News Today AIM ImmunoTech News Today ZIVO Bioscience News Today Senti Biosciences News Today Tevogen Bio News Today NKGen Biotech News Today Coeptis Therapeutics News Today Genetic Technologies News Today BioCardia News Today Organovo News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APTO) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
